AI pharmaceutical company Pathos AI has completed a $237 million Series E funding round, reaching a post-money valuation of $3 billion. The company focuses on applying artificial intelligence to drug discovery and development.
AI pharmaceutical company Pathos AI has completed a $237 million Series E funding round, reaching a post-money valuation of $3 billion. The company focuses on applying artificial intelligence to drug discovery and development.